Sugi Predict

Sugi Predict / Compounds / SCHEMBL29540842

SCHEMBL29540842

SCHEMBL29540842

Cc1cc(C#N)ccc1-n1cc(-c2ccnc3[nH]ccc23)cn1

nearest known ligand 0.55

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ GRM4 Q14833 1/20 0.55
▸ AURKA O14965 1/20 0.54
▸ AURKB Q96GD4 1/20 0.54
▸ INCENP Q9NQS7 1/20 0.54
▸ TPX2 Q9ULW0 1/20 0.54
▸ JAK2 O60674 13/20 0.47
▸ JAK1 P23458 12/20 0.47
▸ JAK3 P52333 4/20 0.47
▸ TYK2 P29597 2/20 0.47
▸ PIK3C3 Q8NEB9 1/20 0.44
▸ PRKCI P41743 1/20 0.43
▸ NUDT1 P36639 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL100680 1.00 GRM4 (0.55) GRM4AURKAAURKBINCENPTPX2
SCHEMBL100420 0.92 GRM4 (0.55) GRM4AURKAAURKBINCENPTPX2
Trifluoroacetic Acid SCHEMBL4093603 0.91 GRM4 (0.49) GRM4AURKAAURKBINCENPTPX2
SCHEMBL29541450 0.88 GRM4 (0.55) GRM4AURKAAURKBINCENPTPX2
SCHEMBL29540957 0.88 GRM4 (0.55) GRM4AURKAAURKBINCENPTPX2
SCHEMBL100917 0.88 GRM4 (0.55) GRM4AURKAAURKBINCENPTPX2
SCHEMBL100383 0.88 GRM4 (0.55) GRM4AURKAAURKBINCENPTPX2
SCHEMBL101067 0.88 GRM4 (0.55) GRM4AURKAAURKBINCENPTPX2
SCHEMBL29541847 0.88 GRM4 (0.55) GRM4AURKAAURKBINCENPTPX2
SCHEMBL100017 0.86 GRM4 (0.55) GRM4AURKAAURKBINCENPTPX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3838903-B1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR INCYTE HOLDINGS CORP (US) 2023-11-22 — — EP disclosed
US-11744832-B2 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors INCYTE CORPORATION (US) 2023-09-05 — — US disclosed
US-20220395506-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION 2022-12-15 — — US disclosed
US-11331320-B2 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2022-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220395506-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK3, JAK1, JAK2 GRM4 2958/4885AURKA 485/4885AURKB 198/4885
US-11744832-B2 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors JAK3, JAK1, JAK2 GRM4 2958/4885AURKA 485/4885AURKB 198/4885
US-11331320-B2 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors JAK3, JAK1, JAK2 GRM4 2958/4885AURKA 485/4885AURKB 198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.